Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children

Bone Marrow Transplantation volume 44, pages 793–797 (2009)Cite this article

Abstract

Iron overload is known to increase complications of hematopoietic SCT (HSCT). We investigated the association of pre-transplant ferritin level with complications and survival after allogeneic HSCT, and evaluated the efficacy of iron-chelating therapy before HSCT. We retrospectively reviewed 101 patients who underwent allogeneic HSCT and divided these patients into three groups: F>1000, patients with ferritin level above 1000 ng/ml at the time of HSCT; F<1000, patients whose ferritin levels were maintained below 1000 ng/ml before HSCT without iron-chelating therapy; IC, patients with ferritin level decreased to less than 1000 ng/ml after iron-chelating therapy before HSCT. In the comparison between the F>1000 group and the F<1000 group, hyperbilirubinemia and treatment-related mortality (TRM) were significantly higher in the F>1000 group. The F>1000 group also showed decreased OS and EFS. In the comparison of the F<1000 and IC groups, there was no significant difference in complications and survival. When compared with the F>1000 group, the IC group showed lower TRM and higher survival. Elevated serum ferritin level was associated with increased TRM and decreased survival, and the analysis of the IC group suggested the benefit of iron-chelating therapy to improve the outcome of HSCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Dürken M, Nielsen P, Knobel S, Finckh B, Herrnring C, Dresow B et al. Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radic Bio Med 1997; 22: 1159–1163.

    Article  Google Scholar 

  2. Evens AM, Mehta J, Gordon LI . Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone marrow transplant 2004; 34: 561–571.

    Article  CAS  PubMed  Google Scholar 

  3. Morado M, Ojeda E, Garcia-Bustos J, Aguado MJ, Arrieta R, Quevedo E et al. BMT: Serum ferritin as risk factor for veno-occlusive disease of the liver: prospective cohort study. Hematology 2000; 4: 505–512.

    Article  CAS  PubMed  Google Scholar 

  4. Altes A, Remacha AF, Sarda P, Baiget M, Sureda A, Martino R et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 2007; 86: 443–447.

    Article  PubMed  Google Scholar 

  5. Altes A, Remacha AF, Sarda P, Sancho FJ, Sureda A, Martino R et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone marrow transplant 2004; 34: 505–509.

    Article  CAS  PubMed  Google Scholar 

  6. Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone marrow transplant 2006; 37: 857–864.

    Article  CAS  PubMed  Google Scholar 

  7. Altes A, Remacha AF, Sureda A, Martino R, Briones J, Canals C et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone marrow transplant 2002; 29: 987–989.

    Article  CAS  PubMed  Google Scholar 

  8. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778–783.

    Article  CAS  PubMed  Google Scholar 

  10. Kang HJ, Kho SH, Jang MK, Lee SH, Shin HY, Ahn HS . Early engraftment kinetics of two units cord blood transplantation. Bone marrow transplant 2006; 38: 197–201.

    Article  CAS  PubMed  Google Scholar 

  11. Kang HJ, Shin HY, Choi HS, Ahn HS . Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone marrow transplant 2004; 34: 939–943.

    Article  CAS  PubMed  Google Scholar 

  12. Maggio A . Light and shadows in the iron chelation treatment of haematological diseases. Br J haematol 2007; 138: 407–421.

    Article  CAS  PubMed  Google Scholar 

  13. Giardini C, Galimberti M, Lucarelli G, Polchi P, Angelucci E, Baronciani D et al. Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia. Br J haematol 1995; 89: 868–873.

    Article  CAS  PubMed  Google Scholar 

  14. Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D et al. Intravenous chelation therapy during transplantation for thalassemia. Haematologica 1995; 80: 300–304.

    CAS  PubMed  Google Scholar 

  15. Ho GT, Parker A, MacKenzie JF, Morris AJ, Stanley AJ . Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy. Eur J Gastroenterol Hepatol 2004; 16: 157–162.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the grants of the Korea Healthcare Technology R&D Project, Ministry of Health, Welfare and Family affairs, Republic of Korea (A070001) and (A080588).

Author information

Author notes

  1. J W Lee and H J Kang: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

    J W Lee, H J Kang, E K Kim, H Kim, H Y Shin & H S Ahn

Authors
  1. J W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H J Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E K Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Y Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H S Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H S Ahn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, J., Kang, H., Kim, E. et al. Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 44, 793–797 (2009). https://doi.org/10.1038/bmt.2009.88

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.88

Keywords

This article is cited by

Search

Advanced search

Quick links